Controlled study of the use of Quetiapine Fumarate in the treatment of Patients with Bipolar Depression
Study identifier:D1447C00135
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Confirmatory Multicenter, Double-blind, Randomized, Placebo controlled Study of the Use of Quetiapine Fumarate (SEROQUEL) in the Treatment of Patients with Bipolar Depression
Medical condition
Bipolar Disorder
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine Fumarate
Sex
All
Actual Enrollment
530
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Jun 2004
Primary Completion Date: -
Study Completion Date: 01 Aug 2005
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Seroquel Medical Science Director
AstraZeneca
